An excerpt from Mool’s published research
Alkem Laboratories Ltd.
NSE: ALKEM · Report 22 Oct 2026
Business model and financial foundation
Alkem Laboratories (NSE: ALKEM), Pharmaceuticals: revenue of ₹14,712 crore in FY26 (+13.5% on FY25), an EBITDA margin of 20.4%, net profit of ₹2,302 crore and net cash of ₹5,474 crore.
Read the analysis and its sources- Revenue, FY26 (₹ crore)
- 14,712
- consolidated
- Revenue growth, FY26
- +13.5%
- on FY25
- EBITDA margin, FY26
- 20.4%
- EBITDA (Operating EBITDA (company definition)) / revenue
The figures retain the periods and comparisons stated in the analysis. This excerpt describes the business; full research access is explained above.